Menu
  • The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • REFINE-ALS

    The purpose of this study is to identify biomarkers to serve as quantifiable measures of Edaravone effects in ALS in those who are initiating clinically prescribed Edaravone treatment for the first time or within one month of consenting. Participants in the study will be followed from enrollment up to 24 weeks after treatment initiation (i.e. 6 treatment cycles).

    Principal Investigator: Shafeeq Ladha, MD

    NeuroSense NST001

    The purpose of this study is to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures, and change in biomarkers. There are six visits required for this study. These visits will happen at the same time as regularly scheduled visits to the BNI ALS Multidisciplinary Clinic, and will occur approximately every 3 months. Overall, participants may be in the research study for about 15 months.

    Principal Investigators: Jeremy Shefner, MD, PhD

    261AS101

    The purpose of this study is to evaluate the safety and tolerability of BIIB100 in adults with ALS. There are three in-person visits, including an overnight inpatient hospital stay where the study medication is administered orally at one time point, and one final phone visit required for this study.

    The trial may last about 7 weeks from the time of screening through the observation period.

    Principal Investigators: Shafeeq Ladha, MD

    233AS101 (SOD1)

    The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of BIIB067 in adults with ALS and confirmed superoxide dismutase 1 (SOD1) mutation. BIIB067 will be administered via lumbar punctures over a 24-week treatment period (i.e. 3 loading doses administered approximately once every 2 weeks, followed by 5 maintenance doses administered approximately once every 4 weeks). Overall, participants will be in the research study for about 32 weeks.

    Principal Investigator: Shafeeq Ladha, MD

     

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.